Given that early cell cycle events are mainly executed by Cdk4/6, in-depth mammalian studies may also have relevance for human disease, because Cdk4/6 inhibitors have gained attraction in the treatment of various forms of cancer, particularly breast cancer [115]. The gene discussed is CDK4; the disease is breast carcinoma.